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Abstract
Bone fillers have emerged as an alternative to the invasive surgery often required to repair skeletal
defects. Achieving controlled release from these materials is desired for accelerating healing.
Here, oppositely-charged Poly (d,l-lactic-co-glycolic acid) (PLGA) nanoparticles were used to
create a cohesive colloidal gel as an injectable drug-loaded filler to promote healing in bone
defects. The colloid self-assembled through electrostatic forces resulting in a stable 3-D network
that may be extruded or molded to the desired shape. The colloidal gel demonstrated shear-
thinning behavior due to the disruption of interparticle interactions as the applied shear force was
increased. Once the external force was removed, the cohesive property of the colloidal gel was
recovered. Similar reversibility and shear-thinning behavior were also observed in colloidal gels
loaded with dexamethasone. Near zero-order dexamethasone release was observed over two
months when the drug was encapsulated in PLGA nanoparticles and simply blending the drug
with the colloidal gel showed similar kinetics for one month. Surgical placement was facilitated by
the pseudoplastic material properties and in vivo observations demonstrated that the PLGA
colloidal gels stimulated osteoconductive bone formation in rat cranial bone defects.
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1.Introduction
Injectable biomaterials that form three-dimensional (3-D) structures in situ are being
pursued as tissue engineering scaffolds [1], biosensors [2] and drug delivery systems [3].
Colloidal gels composed of oppositely-charged nanoparticles at high concentration can
exhibit pseudoplastic behavior facilitating the fabrication of shape-specific macroscale
materials with 3-D architectures [4,5]. Emerging applications in materials science have also
aimed to leverage the unique properties of colloidal gels [6-12]. For example, freeform
printing of colloidal gels may be utilized to produce 3-D, microperiodic networks exhibiting
precise structure [13-16]. The cohesive strength of these materials depends upon
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interparticle interactions such as electrostatic forces, van der Waals attraction, steric
hindrance, etc. [17] which may be leveraged to achieve unique bulk material properties for
many different applications [18-23]. The application of moldable colloidal gels towards
generating tissues has also been proposed [24,25], but has not yet to be applied with the
integration of biodegradable and non-cytotoxic nanoparticles composed of materials
commonly used as tissue scaffolds.
The injectability of 3-D scaffolds is desired as a means to fill tissue defects of irregular size
and shape. Injectable scaffolds are particularly desired in order to avoid the invasive surgery
typically required for tissue implantation [26]. From a clinical perspective, the use of
injectable scaffolds is an attractive alternative to surgery as it reduces the risk of infection,
scar formation, patient discomfort and the cost of treatment [27]. Recently, many scaffolds
that stiffen or solidify in vivo have been applied as injectable scaffolds [28]. Often injectable
scaffolds are polymerized or chemically crosslinked to stiffen the material. Chemically
crosslinked scaffolds normally form via an in situ reaction induced by the presence of water,
heat, light or other stimuli. During solidification, However, toxic chemical agents are
sometimes employed which may adversely affect the scaffolds, destabilize encapsulated
biomolecules, or pose toxicity concerns. On the contrary, colloidal gels that stiffen through
interactions such as electrostatic forces, van der Waals attraction and steric hindrance may
overcome some of these limitations.
Poly (D,L-lactic-co-glycolic acid) (PLGA) is a biodegradable polymer, which has been
widely used in pharmaceutical products and in tissue engineering scaffolds [29-32].
Previously, oppositely-charged PLGA nanoparticles were used to create a cohesive colloidal
gel. The colloid self-assembled through electrostatic forces resulting in a stable, porous 3-D
network that was easily molded to the desired shape [33]. The colloidal gel demonstrated
shear-thinning behavior due to the disruption of interparticle interactions as the applied
shear force was increased. Once the external force was removed, the strong cohesive
property of the colloidal gel was recovered. This material also demonstrated negligible
toxicity to human umbilical cord matrix stem cells (hUCMSCs). The biodegradability,
biocompatibility and reversibility of this unique material make it a potential injectable
scaffold for tissue engineering.
In this paper, PLGA colloidal gels were studied as an injectable controlled release system to
deliver dexamethasone (DEX). DEX is a glucocorticoid which is usually used as an anti-
inflammatory and immunosuppressive agent in bone tissue engineering [34-36]. In addition,
previous reports suggest that glucocorticoids such as DEX may facilitate osteogenesis
[37,38]. Here, DEX was used to investigate the drug release properties of PLGA colloidal
gels. The rheological properties of the drug-loaded colloidal gel were also evaluated and its
application in rat cranial bone defects was assessed.
2.Materials and methods
2.1. Materials
All materials were purchased from Sigma-Aldrich unless otherwise stated. PLGA (75:25)
(inherent viscosity: 0.47 dL/g in chloroform at 30 °C) was purchased from Absorbable
Polymers. DEX was obtained from Alfa Aesar Co. Poly (ethylene-co-maleic acid) (PEMA)
was purchased from Polysciences Inc. Surfactant PEMA [39] and polyvinylamine (PVAm)
[40] were synthesized through reported protocols.
2.2. Preparation of blank PLGA nanoparticles
The oppositely-charged blank PLGA nanoparticles were prepared by a solvent diffusion
method. 100 mg of PLGA was dissolved in 10 mL acetone and then the solution was added
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into 0.2 % PVAm or PEMA (150 mL) surfactant solution through a syringe pump (20 mL/h)
under stirring at 200 rpm overnight to evaporate acetone. Nanoparticles were collected by
centrifugation (Beckman Co., Avanti 30) (16,000 rpm, 20 min). The nanoparticles were
centrifuged and resuspended using deionized water three times to remove excess surfactant.
A fine powder of nanoparticles was obtained by lyophilization for ~2 days.
2.3. Preparation of drug loaded PLGA nanoparticles
PLGA naoparticles loaded with DEX were prepared by a single oil-in-water (O/W)
emulsion/solvent evaporation method [41]. In order to maximize the encapsulation
efficiency (EE) of the DEX in the nanoparticles, different conditions were tested. 90 mg of
PLGA was dissolved in 9 ml dichloromethane and then 10 mg DEX was dissolved in 1 ml
acetone. The DEX in acetone was added to the PLGA in dichloromethane to form the oil
phase. Then 10 ml of the oil phase was added dropwise to a 0.2 % PVAm or PEMA (30 mL)
surfactant solution through a syringe pump (1 mL/min). The oil-in-water (O/W) emulsion
was formed using a high speed homogenizer (Biosepc Products, Inc.) at 16,000 rpm in an
ice bath to prevent overheating. Then the emulsion was added to a 160 ml 0.2 % PVAm or
PEMA surfactant solution under stirring at 200 rpm overnight to evaporate the organic
phase. DEX-loaded nanoparticles were collected by centrifugation (16,000 rpm, 20 min).
The nanoparticles were centrifuged and resuspended using deionized water three times to
remove excess surfactant and free drug. A fine powder of drug loaded nanoparticles was
obtained by lyophilization for ~2 days.
2.4. Preparation of colloidal gels
Lyophilized nanoparticles (PLGA-PVAm or PLGA-PEMA, blank or drug loaded) were
dispersed in deionized water at 20 % wt/vol. These dispersions were mixed in different
ratios to obtain the different PLGA-PEMA: PLGA-PVAm ratios studied. Homogeneous
colloid mixtures were prepared in a bath sonicator for 3 minutes and stored at 4 °C for 2 h
before use. Several gels with different mass ratios of PLGA-PEMA nanoparticles to PLGA-
PVAm nanoparticles were designated as AB73, AB55 and AB37 (A: PLGA-PEMA
nanoparticles; B: PLGA-PVAm nanoparticles; the mass ratio of PLGA-PEMA nanoparticles
to PLGA-PVAm nanoparticles is 70:30, 50:50 and 30:70, respectively).
2.5. Characterization of nanoparticles and colloidal gels
The sizes and zeta potentials of the different PLGA nanoparticles were determined using a
ZetaPALS dynamic light scattering system (Brookhaven, ZetaPALS). All samples were
analyzed in triplicate. Scanning electron microscopy (SEM) was performed using a Jeol
JSM-6380 field emission scanning electron microscope at an accelerating voltage of 10 kV.
2.6. Rheological experiments
Rheological experiments were performed by a controlled stress rheometer (AR2000, TA
Instrument Ltd.). 2° cone steel plates (20 mm diameter) were used and the 500 μm gap was
filled with colloidal gel. A solvent trap was used to prevent evaporation of water. The
viscoelastic properties of the sample were determined at 20°C by forward-and-backward
stress sweep experiments. The viscosity (η) was monitored while the stress was increased
and then decreased (frequency = 1 Hz) in triplicate with 10 minutes between cycles. The gel
recoverability was assessed using the defined time break between cycles. All samples were
analyzed in triplicate.
2.7. In vitro drug release tests
The encapsulation efficiency of DEX in the drug loaded nanoparticles was determined by
dissolving 10 mg of drug-loaded nanoparticles powder in 2 ml trifluoroethanol (TFE).
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Samples were rotated for at least 24 h at 10 rpm to ensure complete dissolution in TFE.
Blank nanoparticles were treated identically. The concentration of DEX in the resulting
solution was determined by measuring the absorbance at 242 nm in a spectrophotometer
(Agilent Technologies, 89090A) and then subtracting the absorbance values for the blank
nanoparticles. All samples were analyzed in triplicate.
DEX release profiles were determined by suspending 800 mg of drug-loaded nanoparticles
in 50 mL of PBS (pH 7.4). The samples were incubated at 37 °C while shaking at 50 rpm in
an incubator/shaker (New Brunswick Scientific C24). At selected time points, the
supernatants were removed and replaced with fresh buffer. The concentration of DEX in the
supernatant was determined using the UV detection method described above. The absorption
of supernatant collected from blank PLGA nanoparticles was negligible at 242 nm
throughout the release study. The amount of drug in each sample was summed with the
amount at each previous time point to obtain the cumulative drug release amount and the
total was divided by the amount of drug in the nanoparticles (encapsulation efficiency times
mass of drug-loaded nanoparticles) to calculate the cumulative drug release percentage.
Each release experiment was performed in triplicate.
2.8. Animals and surgical implantation of colloidal gels
The use of animals and the surgical procedures used in this study were approved by the
Animal Care and Use Committee at the University of Kansas Medical Center, Kansas City,
KS. Male Sprague-Dawley rats, 7 to 8 weeks old, were used in this study. All surgical
procedures were performed under general anesthesia and sterile conditions. A longitudinal
skin incision was made centered over the mid-sagittal suture of the skull. Following careful
dissection and removal of the periosteum, an 8-mm diameter full thickness defect was
produced in the parietal bone using a dental burr. The wound was carefully rinsed with
normal saline to remove any bone debris in the defect, which was an important step in this
procedure for evaluating the formation of new bone within the cranial bone defect as
previously described [42,43]. The cranial defects were filled with injectable PLGA colloidal
gel, PLGA colloidal gel with DEX, or left untreated. The wound was closed with a 5-0
nylon suture. The day of surgery was designated as day “0”. Animals were sacrificed at 4
weeks after surgery and operated calvaria were harvested for histological and histochemical
analyses.
2.9. Histology and histochemistry
To evaluate the cellular and matrix responses to the implants, implanted materials were
retrieved with the surrounding host bone and residual periosteum. Tissue samples were fixed
in 2% paraformaldehyde (Boston BioProducts), pH 7.4, decalcified in 25% formic acid
(Sigma), embedded in paraffin, sectioned at 5 μm, and stained with either hematoxylin and
eosin (H&E) or safranin-O that identifies cartilage cells and cartilage matrix. At least three
animals per treatment group were examined histologically and histochemically.
3.Results and discussions
3.1. Characterization of PLGA nanoparticles and colloidal gels
A schematic representation of the DEX-loaded colloidal gels provides an overview of the
concept (Figure 1). Drug-free PLGA nanoparticles were prepared by a solvent diffusion
method. PLGA dissolved in acetone was titrated into a water phase containing PVAm or
PEMA. The surface charge of particles resulted from the precipitation of PLGA
nanoparticles coated with the respective polyelectrolyte. The particle sizes of drug-free
nanoparticles were 181 ± 15 nm (PLGA-PEMA) and 144 ± 12 nm (PLGA-PVAm). The zeta
potentials of drug-free nanoparticles were -20.1 ± 1.0 mV (PLGA-PEMA) and +32.2 ± 1.3
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mV (PLGA-PVAm) [33]. The DEX-loaded PLGA nanoparticles were prepared by a single
oil-in-water (O/W) emulsion/solvent evaporation method. PLGA and DEX dissolved in a
mixture of dichloromethane and acetone was emulsified into a water phase containing
PVAm or PEMA. The sizes of drug-loaded nanoparticles were 241 ± 26 nm (PLGA-PEMA)
and 182 ± 21 nm (PLGA-PVAm). The zeta potentials of drug-loaded nanoparticles were
-28.5 ± 2.1 mV (PLGA-PEMA) and +34.6 ± 2.5 mV (PLGA-PVAm).
Zeta potential and particle size are two critical factors influencing the cohesive properties of
colloidal gel systems [33]. Small nanoparticles (~100-200 nm) were selected to provide the
desired cohesive strength of colloidal gels. Larger particles yield fewer particle-particle
contacts, thus reducing the gel strength. The large zeta potential of the DEX-loaded
nanoparticles also facilitated tight particle packing as a result of strong electrostatistic
interparticle attraction. These features led to the formation of stable, drug-loaded colloidal
gels. DEX-loaded nanoparticles were linked together into micrometer-scale, ring-like
structures resulting in a bulk porous structure with microchannels. The formation of these
structures is hypothesized to result from an equilibrium of nanoparticle attraction (tight
agglomerates) and repulsion (pores) (Figure 2). Microchannels were ~1 μm in the dry state;
however, these are large in the hydrated state [33]. The entire drug-loaded colloidal gel
exhibited a loosely organized, micro-porous structure which was consistent for different gel
compositions and drug loading percentages. Scanning electron micrographs (SEM) of dried
colloidal gels showed little difference in the structure of the gels containing different mass
ratios of drug-loaded nanoparticles (Figure 2A and 2B), despite the different zeta potential
and particle size of the DEX-loaded PLGA-PEMA and PLGA-PVAm nanoparticles. DEX
loading percentage also did not affect the dry structure of the drug-loaded colloidal gels
(Figure 2C). The appearance of drug-loaded colloidal gels was similar to the unloaded
colloidal gels [33]; molded scaffolds still exhibited stable structure and shape retention when
handled (Figure 2D).
3.2. Rheological properties of PLGA colloidal gels
The strength of colloidal gels depends upon interparticle interactions such as electrostatic
forces and van der Waals attraction [17]. Here, the nanoparticle colloid presumably self-
assembled through long-range electrostatic interactions resulting in a stable 3-D network as
was reported previously [33]. When an external force was applied to disrupt the interparticle
interactions, the colloidal gel demonstrated shear-thinning behavior. Once the external force
was removed, the strong cohesive property of the colloidal gel was recovered. This
reversibility makes the gel an excellent material for molding, extrusion, or injection of tissue
scaffolds. The cohesive strength and the reversibility of colloidal gels depended on the mass
ratios of oppositely-charged nanoparticles and the concentration of the nanoparticles in the
gels [33].
The dependence of lag time on the recovery of colloidal gel viscosity after accelerating/
decelerating shear force cycles was determined for drug-loaded colloidal gels (Figure 3).
The colloidal gels did not rapidly recover during consecutive acceleration/deceleration
cycles of shear force. When no recovery time was allowed, the viscosity of the colloidal gel
only recovered about 30% of the original value. On the contrary, if more time (30 minutes)
was provided for the recovery process, the cohesive property of the colloidal gel was
restored to around 65% of the original value. The results suggested good recoverability for
sheared colloidal gels.
The percentage of drug-loading did not appreciably affect the rheological behavior of
colloidal gels (Figure 4). Meanwhile, colloidal gels with different compositions showed
different viscosity profiles as expected. Equal mass ratios (50:50) of nanoparticles yielded a
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higher viscosity gel (AB55) than an unequal ratio (70:30) of nanoparticles (AB73). The
result confirmed the importance of equilibrating charge as a means to increase cohesion.
3.3. Drug release tests
The encapsulation efficiency of DEX in the nanoparticles depended upon the drug loading
(Figure 5). Because of the slight solubility of DEX in water, some was lost during the
fabrication process. The PLGA-PEMA nanoparticles seemed to encapsulate DEX slightly
more efficiently than PLGA-PVAm nanoparticles; however, the differences were not
statistically significant.
DEX released from the colloidal gels with different drug loading for more than 60 days
when the drug was encapsulated in the PLGA nanoparticles (Figure 6). More drug was
released from the colloidal gel with the highest drug loading (20%) and followed a near zero
order release profile. However, only about half of the drug was released over 60 days due to
the larger amount of drug present at this high loading. On the other hand, almost all drug
was released from 5% drug-loading colloidal gels within 60 days.
Suspensions of purely cationic or anionic drug-loaded nanoparticles released DEX very
quickly (Figure 7). The entire release process only lasted about 15-25 days. Colloidal gels
composed of mixtures of the exact same drug-loaded nanoparticles released the drug for
more than 2 months. Again, the kinetics were near linear regardless of the mass ratio of
charged, drug-loaded nanopaticles in the colloidal gels. For comparison, when the drug was
directly mixed with the colloidal gels, the material still performed as a controlled release
drug delivery system for about 35 days (Figure 8). Slow diffusion of the drug through the
porous microstructure of colloidal gels and, perhaps, adsorption of the drug onto the
nanoparticles, led to the sustained release profile of DEX directly mixed with the colloidal
gel. Furthermore, the time required for drug release from suspensions of purely charged
drug-loaded nanoparticles plus the time required for drug release from colloidal gels mixed
with drug was nearly equal to the duration of drug release from colloidal gels composed of
DEX-loaded nanoparticles. This result was supportive of a two-stage drug release process
from this material.
In previous reports, porous drug delivery systems composed of nanoparticles with
microchannels showed drug release with near zero-order kinetics [44,45]. Presumably, the
drug released from the colloidal gels via a two-stage process. Here, DEX was first released
from the nanoparticles into the micropores of the colloidal gel. In this process, the drug
release rate was faster for colloidal gels containing nanoparticles with higher drug loading,
presumably due to the larger concentration of DEX within nanoparticles driving diffusion.
Then, the released drug diffused through the microchannels and was ultimately transferred
to the media. It appears that, the second process may have been the rate limiting step of this
two step release mechanism. The entire release process exhibited near zero-order release and
colloidal gels with higher drug loading released more drug for a longer duration, but with
similar kinetics.
3.4. Histological and histochemical analyses
Rat cranial defects were used as an in vivo model to test the efficacy of PLGA colloidal gels.
Previous reports suggested that sustained delivery of low doses of DEX may enhance
osteogenesis; therefore, PLGA colloidal gels containing 5% DEX were selected for in vivo
studies [37,38]. Cranial defects were chosen as a model since the current colloidal gel
materials would not be amenable to load-bearing bone regeneration. These materials are
desired for cranial defects, however, since they may conform to irregular defect shapes and
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the viscosity is appropriate for placement and subsequent stiffening in situ. Colloidal gels
are also malleable, which may facilitate the ingrowth of new tissue.
Untreated rat cranial defects were filled with a thin layer of fibrous tissue resulting in a
collapse of the defect area. In contrast, the defects treated with either PLGA colloidal gel or
colloidal gel with DEX were filled with residual implant materials surrounded by either new
bone or fibrous tissue, which effectively prevented the defects from collapsing (Figure 9,
Top row). The formation of new bone, which was observed in the areas adjacent to the host
bone, was substantially more abundant in the defects treated with PLGA colloidal gel (with
or without DEX) compared to the untreated control defects, indicating that PLGA colloidal
gel can stimulate osteoconductive bone formation (Figure 9, Middle and Bottom rows). The
central regions of the defects treated with PLGA colloidal gel were filled with residual
implant materials and fibrous tissue without new bone, suggesting that complete bone
healing was not achieved in 8-mm critical-sized cranial defects even in the presence of the
colloidal gel implants. A combination of osteoconductive biomaterials and osteoinductive
factor(s)/osteogenic cells may be required to achieve complete bone regeneration of critical-
sized rat cranial bone defects. No cartilage formation was observed in the PLGA colloidal
gel-treated or untreated defects. These results suggest that PLGA colloidal gels are non-
cytotoxic in vivo and highly osteoconductive for the repair of rat cranial bone defects.
4.Conclusions
Cohesive colloidal gels made by mixing oppositely-charged PLGA nanoparticles were
investigated as potential bone defect fillers. The strength of the colloidal gels resulted from
electrostatic interparticle interactions. The pseudoplastic, shear-thinning behavior of the
colloidal gels was desired for applications as an injectable scaffold for tissue repair. The
PLGA colloidal gel also exhibited recovery of viscosity after shear shinning suggesting that
the material may stiffen after placement in vivo. Drug release tests revealed that DEX was
slowly released at a constant rate for more than two months. In vivo results demonstrated
that PLGA colloidal gels were osteoconductive fillers capable of controlled release for the
repair of rat cranial bone defects.
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Schematic representation of the properties of DEX-loaded colloidal gels.
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Scanning electron micrographs of AB55 colloidal gel with 10% DEX loading (A), AB73
colloidal gel with 10% DEX loading (B), AB55 colloidal gel with 20% DEX loading (C)
and shaped tissue scaffold made from AB55 colloidal gel with 10% DEX loading (D) (scale
bar = 1μm).
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Viscosity profiles demonstrate the shear-thinning behavior of AB55 colloidal gel with 10%
DEX loading for accelerating (solid symbols) and decelerating (open symbols) shear force
using different lag times between cycles.
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Viscosity profiles demonstrate the shear-thinning behavior of AB55 and AB73 colloidal gel
with different DEX loading for accelerating (solid symbols) and decelerating (open
symbols) shear force.
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Encapsulation efficiency of DEX in PLGA-PEMA and PLGA-PVAm nanoparticles with
different loading percentage.
Wang et al. Page 14














Drug release profiles of AB55 colloidal gels with different DEX loading. Drug was loaded
into both positively charged and negatively charged PLGA nanoparticles.
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Drug release profiles of colloidal gels mixed at different ratios with 10% DEX loading. Drug
was loaded into both positively charged and negatively charged PLGA nanoparticles (NPs).
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Drug release profiles of AB55 colloidal gels with 10% DEX directly mixed into the bulk
material (round) compared to the drug encapsulated in both nanoparticle types (square).
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Photomicrographs of tissue sections prepared from untreated, PLGA colloidal gel (PLGA
gel)-treated, or PLGA colloidal gel with encapsulated DEX (PLGA gel + DEX)-treated rat
cranial bone defects. Top row: Low magnification of tissue sections including the bone
defect margins (arrows) and the mid-portion of the defects (arrow heads). S-O, safranin-O
and fast-green staining. Middle row: Higher magnification of tissue sections showing both
the original host bone (ob) and the new bone (nb) formed in the areas adjacent to the host
bone. New bone is outlined by a dotted line. H&E, hematoxylin and eosin staining. Bottom
row: Polarizing photomicrographs (POL) of the cranial defect margins demonstrate that
collagen fibers of the new bone (nb) display non- or low-polarizing orientation compared to
that of the highly polarized parallel lamellae of the original host bone (ob) in each treatment
group. H&E staining. Scale bar = 100 μm for all photos in this figure.
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